Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study.

ABSTRACT:

Background

Hepatocellular carcinoma (HCC) is an aggressive form of liver cancer with increasing incidence and mortality worldwide. For metastatic disease, systemic treatment is recommended. In addition to tumor characteristics, adverse events (AEs) may influence regimen choice.

Aim

To analyze healthcare burden among patients with advanced HCC, by treatment type and AEs observed.

Methods

Included were adult commercial and Medicare Advantage enrollees with ≥2 non-diagnostic claims coded for HCC (the first setting the index date); ≥1 claim for systemic treatment of advanced/metastatic HCC; and continuous enrollment for a 6-month pre-index baseline period to ≥1 month post-index (follow-up). Patients were excluded by lack of systemic treatment; incomplete demographic infor

SUBMITTER: Lal LS 

PROVIDER: S-EPMC9124510 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature